Pfizer names new head of IR

Jul 22, 2021
Christopher Stevo joins from Nasdaq-listed Alexion Pharmaceuticals

Pharmaceutical and biotechnology giant Pfizer has appointed Christopher Stevo as senior vice president and chief investor relations officer.

He now reports to Sally Susman, chief corporate affairs officer. He succeeds Chuck Triano, who previously announced his intent to retire after 13 years at Pfizer. Triano will stay on through the end of September to help with the transition.

Pfizer is headquartered in New York and listed on the NYSE.

Most recently, Stevo was head of investor relations at Alexion Pharmaceuticals. Before his role at Alexion, he served as a senior equity analyst for Amundi US, where he was responsible for a portfolio of US healthcare stocks covering all sub-sectors.

He has also held several leadership roles at Putnam Investments, a financial services firm based in Boston, Massachusetts, where he specialized in international healthcare, including the co-management of a $1.2 bn global healthcare fund.

‘As the new head of investor relations, Chris brings a wealth of experience with buy-side equity analysts and a strong network of relationships across the investment community,’ says Albert Bourla, chairman and CEO of Pfizer, in a statement.

‘His deep knowledge of the healthcare industry will be a great asset as we continue to advance our innovative pipeline to deliver breakthrough therapies and vaccines to patients and long-term value for shareholders.’

Sign up to get stories direct to your inbox
logo-black logo-black